Satisfact-Home: Perception of Care Quality and Quality of Life in Patients With Solid Tumors Receiving Immune Checkpoint Inhibitors (ICIs) Therapy From Hospital To Home: A French Multicenter Prospective Observational Study
Author(s)
Anne Claire Toffart, MD, PhD1, Cécile Di Santolo, MD2, Laure Guéroult-Accolas, Ms3, Nicolas Meyer, MD, PhD4, Audrey Rabeau, MD5, Aldo Renault, MD6, HERVE LEMASSON, MA7, Nathalie Texier, PharmD8, Florence Brellier, MSc, PhD9, veronique MOREAU MALLET, MD7, Maurice Pérol, MD10.
1Grenoble University Hospital Center, Grenoble, France, 2HAH HADAN, Vandoeuvre-les-Nancy, France, 3Patients Network Association, Paris, France, 4Medipole Garonne Clinic, Toulouse, France, 5Larrey Hospital, Toulouse University Hospital, Toulouse, France, 6Pau Hospital Center, Pau, France, 7Bristol Myers Squibb, Rueil Malmaison, France, 8Kappa Santé, Paris, France, 9Bristol Myers Squibb, Uxbridge, United Kingdom, 10Léon Bérard Cancer Center, Lyon, France.
1Grenoble University Hospital Center, Grenoble, France, 2HAH HADAN, Vandoeuvre-les-Nancy, France, 3Patients Network Association, Paris, France, 4Medipole Garonne Clinic, Toulouse, France, 5Larrey Hospital, Toulouse University Hospital, Toulouse, France, 6Pau Hospital Center, Pau, France, 7Bristol Myers Squibb, Rueil Malmaison, France, 8Kappa Santé, Paris, France, 9Bristol Myers Squibb, Uxbridge, United Kingdom, 10Léon Bérard Cancer Center, Lyon, France.
OBJECTIVES: ICIs have transformed cancer treatment, markedly improving overall survival for patients with various solid tumors. While traditionally administered in outpatient hospital (OH) settings, there has been a recent shift towards hospital at home (HAH) ICI administration in France. The study evaluates patient satisfaction with care, quality of life (QoL), expectations, and experiences during the transition from OH to HAH for ICI administration.
METHODS: Patients receiving ICIs for advanced solid tumors in OH and considered by oncologists for the first time eligible for HAH were enrolled in this prospective, observational study across 11 participating French sites. At enrolment, they completed EORTC PATSAT-C33 (care satisfaction, 100 points) and FACT-G7 (QoL, 28 points) self-questionnaires regardless of the decision to transition to HAH. Patients who transitioned to HAH were followed for up to 24 weeks, completing the same questionnaires. We present an initial descriptive analysis.
RESULTS: The study included 49 patients (71.4% male, mean age 70.7±8.5 years) with ECOG-PS of 0-1 in 87.7% and ICIs received for an average of 13.6± 8.8 months. Among them, 85.7% had advanced metastatic cancer, including 81.6% with bronchopulmonary cancer. Of the 49 patients, 38 (77.5%) agreed to transition to HAH, primarily for: better organization of daily life (65.6%), more time with friends and family (43.8%) and time savings for themselves (31.3%). Overall care satisfaction (PATSAT-C33 score) remained stable: 74.1±8.5 at initial OH measure and 71.4±18.9 at the last follow-up HAH measure in HAH (n=28). FACT-G7 scores showed a slight improvement from 17.8±4.3 to 19.1±4.5 (mean change:1.6; 95% IC: 0.1;2.9). At 24 weeks, 83% of patients preferred HAH over OH with 94.5% feeling secure during ICI administration at home, and 77.7% experiencing improved well-being.
CONCLUSIONS: Care satisfaction was maintained during the transition to HAH for ICI administration, and patients perceived the improved quality of life and well-being that they had anticipated.
METHODS: Patients receiving ICIs for advanced solid tumors in OH and considered by oncologists for the first time eligible for HAH were enrolled in this prospective, observational study across 11 participating French sites. At enrolment, they completed EORTC PATSAT-C33 (care satisfaction, 100 points) and FACT-G7 (QoL, 28 points) self-questionnaires regardless of the decision to transition to HAH. Patients who transitioned to HAH were followed for up to 24 weeks, completing the same questionnaires. We present an initial descriptive analysis.
RESULTS: The study included 49 patients (71.4% male, mean age 70.7±8.5 years) with ECOG-PS of 0-1 in 87.7% and ICIs received for an average of 13.6± 8.8 months. Among them, 85.7% had advanced metastatic cancer, including 81.6% with bronchopulmonary cancer. Of the 49 patients, 38 (77.5%) agreed to transition to HAH, primarily for: better organization of daily life (65.6%), more time with friends and family (43.8%) and time savings for themselves (31.3%). Overall care satisfaction (PATSAT-C33 score) remained stable: 74.1±8.5 at initial OH measure and 71.4±18.9 at the last follow-up HAH measure in HAH (n=28). FACT-G7 scores showed a slight improvement from 17.8±4.3 to 19.1±4.5 (mean change:1.6; 95% IC: 0.1;2.9). At 24 weeks, 83% of patients preferred HAH over OH with 94.5% feeling secure during ICI administration at home, and 77.7% experiencing improved well-being.
CONCLUSIONS: Care satisfaction was maintained during the transition to HAH for ICI administration, and patients perceived the improved quality of life and well-being that they had anticipated.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
PCR212
Topic
Health Service Delivery & Process of Care, Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Oncology